Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib

Podobné jednotky

• Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
  Autor: Weber, Britta, a další
  Vydáno: (2014)
• The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
  Autor: Demuth, Christina, a další
  Vydáno: (2018)
• Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
  Autor: Wang, Xiaofei, a další
  Vydáno: (2017)
• Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
  Autor: Winther-Larsen, Anne, a další
  Vydáno: (2016)
• The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
  Autor: Jakobsen, Kristine Raaby, a další
  Vydáno: (2016)